← All companies ← BGIN Manual BGSI → ← BCYC Pharmaceuticals BHC →
BGM, BGM Group Ltd.
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
- What moves the needle
- Gross margin has run about 15% and operating margin about 4.2% through the cycle, a thin spread that turns the result on volume and the cost of what it sells far more than on the price it sets. The margin is cyclical, swinging between −5.6% and 13% over the years, so the through-cycle figure carries more than any single year — and the balance sheet at the trough more than the peak. Inventory runs near 20% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median 5%, above 15% in 2 of 6 years). Owner earnings, the cash-based check, have been thin too. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2018–2024
realized figures from each filing · older years to the left| 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | TTMTTMMar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| $50M | $46M | $50M | $57M | $65M | $46M | $25M | $27M | RevenueRevenue |
| 16% | 21% | 15% | 10% | 10% | 4% | 16% | 19% | Gross marginGross mgn |
| $6M | $6M | $5M | $2M | $2M | ($3M) | ($564K) | ($2M) | Operating incomeOp. inc. |
| 11.9% | 13.4% | 9.6% | 4.2% | 3.2% | −5.6% | −2.2% | −7.9% | Operating marginOp. mgn |
| $5M | $6M | $5M | $3M | $1M | ($8M) | ($2M) | ($3M) | Net incomeNet inc. |
| 15% | 15% | 15% | 8% | 12% | — | — | — | Effective tax rateTax rate |
| Cash flow & returns | ||||||||
| $4M | ($580K) | $5M | $345K | $13M | $312K | $544K | ($5M) | Operating cash flowOp. cash |
| $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | DepreciationDeprec. |
| ($2M) | ($8M) | ($970K) | ($4M) | $10M | $7M | $824K | ($4M) | Working capital & otherWC & other |
| $1M | $616K | $450K | $1M | $2M | $180K | $240K | $472K | CapexCapex |
| 2.2% | 1.3% | 0.9% | 2.6% | 3.1% | 0.4% | 1.0% | 1.8% | Capex / revenueCapex/rev |
| $3M | ($1M) | $5M | ($1M) | $11M | $132K | $304K | ($6M) | Owner earningsOwner earn. |
| 6.6% | −2.6% | 9.2% | −2.0% | 16.4% | 0.3% | 1.2% | −20.7% | Owner earnings marginOE mgn |
| $3M | ($1M) | $5M | ($1M) | $11M | $132K | $304K | ($6M) | Free cash flowFCF |
| 6.6% | −2.6% | 9.2% | −2.0% | 16.4% | 0.3% | 1.2% | −20.7% | Free cash flow marginFCF mgn |
| $734K | — | — | — | — | $2M | — | $2M | Dividends paidDiv. paid |
| — | 34% | 29% | 5% | 5% | -6% | -1% | -1% | ROICROIC |
| — | 30% | 19% | 6% | 3% | -19% | -4% | -1% | Return on equityROE |
| Balance sheet | ||||||||
| — | $5M | $12M | $10M | $14M | $8M | $10M | $11M | Cash & investmentsCash+inv |
| — | $604K | $1M | $2M | $815K | $2M | $2M | $6M | ReceivablesReceiv. |
| — | $13M | $12M | $12M | $9M | $5M | $5M | $9M | InventoryInvent. |
| — | $4M | $4M | $7M | $5M | $4M | $4M | $8M | Accounts payablePayables |
| — | $10M | $9M | $8M | $4M | $3M | $2M | $6M | Operating working capitalOper. WC |
| — | $25M | $38M | $40M | $30M | $35M | $30M | $43M | Current assetsCur. assets |
| — | $12M | $18M | $18M | $9M | $7M | $9M | $24M | Current liabilitiesCur. liab. |
| — | 2.1× | 2.0× | 2.2× | 3.3× | 5.2× | 3.4× | 1.8× | Current ratioCurr. ratio |
| — | $35M | $48M | $75M | $65M | $51M | $53M | $207M | Total assetsAssets |
| — | ($5M) | ($12M) | ($10M) | ($14M) | ($8M) | ($10M) | ($11M) | Net debt / (cash)Net debt |
| 27.6× | 27.6× | 19.8× | 41.4× | — | — | — | -36.8× | Interest coverageInt. cov. |
| — | $20M | $26M | $55M | $53M | $43M | $43M | $182M | Shareholders’ equityEquity |
| Per share | ||||||||
| 450M | 450M | 450M | 511M | 108M | 108M | 108M | 98.3M | Shares out (diluted)Shares |
| $0.11 | $0.10 | $0.11 | $0.11 | $0.60 | $0.43 | $0.23 | $0.27 | Revenue / shareRev/sh |
| $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $-0.07 | $-0.01 | $-0.03 | EPS (diluted)EPS |
| $0.01 | $-0.00 | $0.01 | $-0.00 | $0.10 | $0.00 | $0.00 | $-0.06 | Owner earnings / shareOE/sh |
| $0.01 | $-0.00 | $0.01 | $-0.00 | $0.10 | $0.00 | $0.00 | $-0.06 | Free cash flow / shareFCF/sh |
| $0.00 | — | — | — | — | $0.02 | — | $0.02 | Dividends / shareDiv/sh |
| $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 | $0.00 | Cap. spending / shareCapex/sh |
| — | $0.04 | $0.06 | $0.11 | $0.49 | $0.39 | $0.39 | $1.85 | Book value / shareBVPS |
The diluted share count moved ×1/4.72 into 2022 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.
Share counts before TTM are restated ×15 for a stock split, so per-share figures sit on one basis.
| 6-yr | 5-yr | |
|---|---|---|
| Revenue / share | +12.9%/yr | +17.7%/yr |
| Owner earnings / share | −14.9%/yr | — |
| Dividends / share | +58.8%/yr (5-yr) | +58.8%/yr |
| Capital spending / share | −1.9%/yr | +10.1%/yr |
| Book value / share | +54.9%/yr (5-yr) | +54.9%/yr |
The record, charted
FY2018–2024Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2024 the business turned a $2M loss into $304K of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|
| Reported net income | ($2M) | ($8M) | $1M | $3M | $5M |
| Depreciation & amortizationnon-cash charge added back | +$1M | +$1M | +$1M | +$1M | +$1M |
| Working capital & othertiming of cash in and out, other non-cash items | +$824K | +$7M | +$10M | −$4M | −$970K |
| Cash from operations | $544K | $312K | $13M | $345K | $5M |
| Capital expenditurecash put back in to keep running and to grow | −$240K | −$180K | −$2M | −$1M | −$450K |
| Owner earnings | $304K | $132K | $11M | ($1M) | $5M |
| Owner-earnings marginowner earnings ÷ revenue | 1% | 0% | 16% | -2% | 9% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
“To remedy our identified material weakness identified to date, we have implemented and plan to implement a number of measures to strengthen our internal control over financial reporting, including (i) recruiting more financial reporting and accounting…”
The figures below are only as sound as the controls that produced them. read the note →
Will it survive?
- Can it pay its interest? -36.8×Does not cover its interestOperating income ($2M) ÷ interest expense $58K
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net cash, debt-freeCash $10M + ST investments $1M − debt $0
What this means
Cash and short-term investments exceed every dollar of debt by $11M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 75 + DIO 149 − DPO 142 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Not enough dataIndustry peers: median -85%
What this means
The filing data didn't include the inputs for this check.
- Thin through the cycle7-yr median margin, range -3%–16%; latest ($6M) = operating cash ($5M) − maintenance capex $472KIndustry peers: median -504%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -21% of revenue this year, a 1% median across 7 years.
- Loss, and burning cashNet income ($3M) · cash from operations ($5M)
In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- No surplus to allocate
What this means
The business didn't generate positive Owner Earnings this year, so any distributions came from the balance sheet or borrowing, not from operations.
- Investing or harvesting? 0.42×HarvestingCapex $472K ÷ depreciation $1M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 0 of 5 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $27M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity NearCurrent ratio ≥ 2× · 1.82×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Earnings stability MissA profit every year (7-yr record) · 2 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · 2 of 7 yrs
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth MissEarnings +33% over the record · −152%
What this means
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.09/share (latest year $-0.08), the averaged base the calculator's gate runs on, and book value is $5.76/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2018–2024
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 5 of 7
What this means
Lost money in 2 year(s), look at what happened there before trusting the average.
- Operating margin 12% → −2% (3-yr avg ends)
In the filing’s words The filing attributes gains to higher prices, but the margin in the record has not followed — the claim outruns the result here.
What this means
Through the cycle the operating margin slipped — about 12% early to −2% lately, median 4% — competition or costs are biting in.
- Owner earnings growth −23%/yr
What this means
Owner earnings shrank about 23% a year over the record.
- Worst year 2023 · −5.6% op. margin
What this means
Operations went underwater in 2023, understand why before trusting the good years.
- Dividend record rising
What this means
Paid and raised the dividend across the record, the continuity Graham prized.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product; it frames AI mainly as a capability.
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Mar 31, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$11M
- Receivables$6M
- Inventory$9M
- Other current assets$18M
- Accounts payable$8M
- Other current liabilities$15M
From the company's latest filing.
How the cash was used, 2018–2024
Over the record, the business generated $23M of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested$6M · 27%
- Dividends$3M · 11%
- Retained (debt / cash)$14M · 62%
- Returned to owners$3M
15% of the owner earnings the business produced over the span, $3M as dividends and $0 as buybacks.
- Net change in share count−78.2%
The diluted count fell from 450M to 98M, so the buybacks outran the stock issued to staff.
- Dividend record$0.02/sh
Paid in 2 of the years on record, the per-share dividend growing about 911% a year. It was never cut over the span.
- Return on what it retained17%
Of the earnings it kept rather than paid out ($8M over the span), annual owner earnings (first three years vs last three) grew $1M, so each retained $1 added about 0.17 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Acquisitions & goodwill
from the balance sheet & the 7-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 7-year record, from the company's own filings.
Inverting the record
Invert: instead of why BGM Group Ltd. is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2018–2024.
None of the 3 tests turned up a mark; each came back clean. A clean panel says only that these particular ways of being wrong are not written into the record.
- Is it less profitable than it was?
- Did the share count rise anyway?
- Did reported profit become cash?
Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.
What an owner would ask, FY2024
read the 10-K →- How much of the revenue rides on one buyer?≈$4M · 16% of revenue on the largest customers (TTM)
“For the year ended September 30, 2024, two customers accounted for 16 % and 12 % of total revenue, respectively and two major vendors accounted for 12 % and 10 % of the total purchase, respectively.”verify →
The questions the record and the charts do not answer on their own; each carries the figure and the place to look.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| AQSTAquestive Therapeutics Inc. | $45M | 60% | -72.6% | — | -62% |
| PVLAPalvella Therapeutics Inc. | $43M | — | -124.9% | — | -77% |
| WVEWave Life Sciences Ltd. | $43M | — | -935.3% | — | -512% |
| RCUSArcus Biosciences Inc. | $33M | — | -656.8% | -55% | -503% |
| VSTMVerastem Inc. | $31M | 99% | -758.1% | -78% | -794% |
| BGMBGM Group Ltd. | $27M | 15% | 4.2% | 5% | 1% |
| ALMSAlumis Inc. | $24M | — | -1886.9% | -169% | -1539% |
| NAMSNewAmsterdam Pharma Company N.V. | $23M | — | -694.9% | -92% | -504% |
| Group median | — | 60% | -675.8% | -78% | -503% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the US price, in dollars: the NYSE/Nasdaq quote you hold. BGM Group Ltd.'s US listing is the ordinary share itself. The record tables elsewhere on this page remain as filed.
Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what BGM Group Ltd. has delivered.
BGM Group Ltd.’s latest year shows negative owner earnings, a cyclical trough. So the tool opens on the through-cycle base, the cash it would earn at rest; clear the toggle below to read the latest year exactly as reported.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings ($6M) on 32M shares outstanding (a weighted average, the only count this filer tags); net cash $11M. The if-converted diluted count is 98M, 211% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base opens on the through-cycle figure (the latest year sits off the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← BGIN its page in the Manual BGSI →
Industry order: ← BCYC the Pharmaceuticals chapter BHC →